





















- [40] Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. *Clinical Chemistry* 2002; 48:261–268.
- [41] Menini T, Gugliucci A. Paraoxonase 1 in neurological disorders. *Redox Report* 2014;19:49–58.
- [42] Yang Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). *Biochimica et Biophysica Acta* 2009; 1790(3): 155-160.
- [43] Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. *Free Radical Biology & Medicine* 1999; 26(7-8):892-904.
- [44] Uz T, Pesold C, Longone P, Manev H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. *FASEB Journal* 1998; 12(6):439–449.
- [45] Czapski GA, Czubowicz K, Strosznajder JB, Strosznajder RP. The lipoxygenases: their regulation and implication in Alzheimer's disease. *Neurochemistry Research* 2016; 41(1–2): 243–57.
- [46] Chu J, Praticò D. The 5-Lipoxygenase as modulator of Alzheimer's  $\gamma$ -secretase and therapeutic target. *Brain Research Bulletin* 2016; 126(Pt 2): 207–212.
- [47] Horrillo R, Planagumà A, González-Pérez A, Ferré N, Titos E, Miquel R, López-Parra M, et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. *Journal of Pharmacology and Experimental Therapeutics* 2007; 323 (3):778-786.
- [48] Martínez-Clemente M, Ferré N, González-Pérez A, López-Parra M, Horrillo R, Titos E et al. 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor  $\alpha$ -induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. *Hepatology* 2010; 51(3): 817-827.
- [49] Ying W, Chen Y, Alano CC, Swanson RA. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. *Journal of Cerebral Blood Flow & Metabolism* 2002; 22(7):774–779.
- [50] Izumi Y, Zorumski CF. Neuroprotective effects of pyruvate following NMDA-mediated

excitotoxic insults in hippocampal slices. *Neuroscience Letters* 2010; 478(3):131–135.

- [51] Haces ML, Hernandez-Fonseca K, Medina-Campos ON, Montiel T, Pedraza-Chaverri J, Massieu L. Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. *Experimental Neurology* 2008; 211(1):85–96.

### **Competing Interests:**

No competing interests to disclose.

### **Contribution of Individual Authors to the Creation of a Scientific Article (Ghostwriting Policy)**

All authors contributed equally to the manuscript, read and approved the final version.

### **Sources of Funding for Research Presented in a Scientific Article or Scientific Article Itself**

This work is not supported by research grants.

### **Creative Commons Attribution License 4.0 (Attribution 4.0 International, CC BY 4.0)**

This article is published under the terms of the Creative Commons Attribution License 4.0

[https://creativecommons.org/licenses/by/4.0/deed.en\\_US](https://creativecommons.org/licenses/by/4.0/deed.en_US)

### **Publication Ethics for Researches Involving Human Subjects**

Not applicable.

### **Publication Ethics for Researches Involving Animals**

The study was conducted in accordance with the recommendations the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985) and the recommendations for the proper care and use of laboratory animals (Directive 2010/63/EU revising Directive 86/609/EEC on the protection of animals used for scientific purposes). The article is comply with the guidelines of ARRIVE.

### **Publication Ethics for Researches Involving Plants**

Not applicable.